Edgestream Partners L.P. Acquires 8,475 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Edgestream Partners L.P. boosted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2,442.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 8,822 shares of the biopharmaceutical company’s stock after purchasing an additional 8,475 shares during the quarter. Edgestream Partners L.P.’s holdings in Regeneron Pharmaceuticals were worth $6,284,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Mizuho Securities USA LLC boosted its position in shares of Regeneron Pharmaceuticals by 625.5% during the 3rd quarter. Mizuho Securities USA LLC now owns 59,341 shares of the biopharmaceutical company’s stock valued at $62,382,000 after acquiring an additional 51,162 shares during the last quarter. Principal Financial Group Inc. grew its holdings in shares of Regeneron Pharmaceuticals by 1.7% in the third quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company’s stock valued at $181,961,000 after purchasing an additional 2,828 shares in the last quarter. Simplify Asset Management Inc. grew its holdings in shares of Regeneron Pharmaceuticals by 50.8% in the third quarter. Simplify Asset Management Inc. now owns 9,591 shares of the biopharmaceutical company’s stock valued at $10,082,000 after purchasing an additional 3,231 shares in the last quarter. Golden State Equity Partners grew its holdings in shares of Regeneron Pharmaceuticals by 1,479.1% in the fourth quarter. Golden State Equity Partners now owns 1,358 shares of the biopharmaceutical company’s stock valued at $967,000 after purchasing an additional 1,272 shares in the last quarter. Finally, Fagan Associates Inc. grew its holdings in shares of Regeneron Pharmaceuticals by 42.2% in the fourth quarter. Fagan Associates Inc. now owns 12,923 shares of the biopharmaceutical company’s stock valued at $9,205,000 after purchasing an additional 3,832 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Analyst Ratings Changes

REGN has been the subject of a number of recent research reports. Robert W. Baird cut their target price on shares of Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating for the company in a report on Wednesday, February 5th. TD Cowen decreased their price target on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating on the stock in a report on Tuesday, February 4th. Bank of America restated an “underperform” rating and issued a $565.00 price target on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 10th. Wells Fargo & Company lowered their price target on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating for the company in a research report on Friday, January 10th. Finally, Canaccord Genuity Group downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, December 17th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $973.13.

Regeneron Pharmaceuticals Price Performance

REGN opened at $698.44 on Friday. The business’s 50-day moving average is $696.22 and its two-hundred day moving average is $856.82. Regeneron Pharmaceuticals, Inc. has a 1 year low of $642.00 and a 1 year high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The firm has a market capitalization of $76.36 billion, a PE ratio of 18.25, a price-to-earnings-growth ratio of 2.34 and a beta of 0.08.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. During the same quarter in the previous year, the firm earned $11.86 earnings per share. The company’s revenue was up 10.3% on a year-over-year basis. Research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be paid a dividend of $0.88 per share. The ex-dividend date of this dividend is Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.50%. Regeneron Pharmaceuticals’s payout ratio is 2.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.